Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardinal Health (CAH – Research Report) and Apyx ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this article, we are going to take a ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

The rapper has mastered the delicate balance between commercial success and politically charged music. How far will he push ...

Average Diluted Shares Outstanding: 243 million, 1% lower than a year ago. Cardinal Health Inc (NYSE:CAH) reported strong second quarter results, driven by robust demand in pharmaceutical and ...